bristol myers squibb food and drug administration news - Search News

Bristol Myers Squibb Stock Rises

Investopedia on MSN · 2d

Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval

Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.

Seeking Alpha · 1d

Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.

Wall Street Journal · 2d

Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug

Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel treatment for schizophrenia. Bristol-Myers shares stood about 6% higher in recent premarket trading,

2don MSN

Bristol-Myers Squibb stock jumps on schizophrenia drug approval

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

Business Wire2d

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

2d

New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results